Trial intelligence / Profile preview

Cellular immune response after infant Prevenar vaccination

NL-OMON26266Active, not recruiting

Sponsor
Intravacc
Start
Dec 2008
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Open-label trial of pneumococcal 7-valent conjugate vaccine in pneumococcal disease (4 arms), sponsored by Intravacc. Primary endpoint: Cellular immunogenicity. Started Dec 2008; status: active, not recruiting.

02

Drugs

pneumococcal 7-valent conjugate vaccine
03

Conditions

pneumococcal disease

Beyond the preview

Go deeper on NL-OMON26266.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON26266.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call